caffeine has been researched along with Infant, Premature, Diseases in 189 studies
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared." | 9.51 | Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022) |
| " Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation." | 9.41 | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023) |
| "There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy." | 9.41 | Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021) |
| "To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants." | 9.34 | [Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020) |
| "Caffeine is effective in the treatment of apnea of prematurity." | 9.27 | Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 9.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity." | 9.24 | Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 9.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD." | 9.22 | Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 9.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 9.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants." | 9.22 | [Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016) |
| "It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants." | 9.22 | Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016) |
| "• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years." | 9.20 | High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015) |
| "Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication." | 9.19 | The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014) |
| "This retrospective study reviewed weight gain, time to reach full feeds and time to cease caffeine in PBs previously enrolled in the RCT." | 9.19 | CeasIng Cpap At standarD criteriA (CICADA): impact on weight gain, time to full feeds and caffeine use. ( Abdel-Latif, ME; Broom, M; Shadbolt, B; Stewart, A; Todd, DA; Wright, A; Ying, L, 2014) |
| "Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system." | 9.19 | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 9.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial." | 9.14 | Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed." | 9.12 | Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 9.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 9.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 9.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 9.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 9.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 9.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 8.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 8.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| " It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity." | 8.90 | Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014) |
| "Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems." | 8.87 | Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011) |
| "Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult." | 8.86 | [Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 8.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates." | 8.81 | Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 8.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 8.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 8.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 8.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity." | 8.12 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 8.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity." | 7.96 | Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020) |
| " Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords." | 7.83 | [Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016) |
| " We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity." | 7.80 | Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014) |
| " Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis." | 7.79 | Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013) |
| "To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age." | 7.77 | Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011) |
| "Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies." | 7.73 | [Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age." | 7.73 | [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| " This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea." | 7.71 | Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001) |
| "To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications." | 7.70 | Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000) |
| "Apnea of prematurity is a common problem in neonatal intensive care nurseries." | 7.68 | Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 7.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"." | 7.67 | [Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987) |
| "This review provides an understanding of current problems related to apnea of infancy." | 7.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| "The efficacy of low and high dose caffeine on idiopathic bradycardia and hypoxaemia was tested in premature infants." | 7.67 | [Effectiveness of low- and high-dose caffeine on idiopathic bradycardia and hypoxemia in premature infants]. ( Bucher, HU; Duc, G; Fallenstein, F; Mieth, D, 1985) |
| "The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea." | 7.66 | Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 7.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule." | 7.66 | Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979) |
| "To examine 5-year outcomes in children enrolled in a pilot randomized controlled trial of a high loading dose of caffeine after preterm birth." | 5.51 | Five-year outcomes of premature infants randomized to high or standard loading dose caffeine. ( Cyr, PEP; Inder, TE; Lean, RE; McPherson, C; Rogers, CE; Smyser, CD, 2022) |
| "In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared." | 5.51 | Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022) |
| " Further studies should focus on the timing and dosage of caffeine to optimize the prevention of AKI." | 5.48 | Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study. ( Askenazi, DJ; Boohaker, LJ; Carmody, JB; Charlton, JR; Griffin, RL; Guillet, R; Harer, MW; Selewski, DT; Swanson, JR, 2018) |
| " Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation." | 5.41 | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023) |
| "There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy." | 5.41 | Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021) |
| "To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants." | 5.34 | [Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020) |
| " There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0." | 5.34 | Early application of caffeine improves white matter development in very preterm infants. ( Liu, S; Liu, Y; Wang, X; Xu, F; Yang, L; Yuan, X; Zhang, R; Zhang, X; Zhu, C, 2020) |
| " In conclusion, cisapride has a positive influence on GOR parameters during caffeine treatment without impairing the oral bioavailability or therapeutic effect of caffeine." | 5.31 | Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine. ( Baisch, HJ; Heimann, G; Kentrup, H; Kusenbach, G; Skopnik, H, 2000) |
| "The study was performed using information on echocardiography measurements from preterm neonates recruited for apnea of prematurity (75 of 240) and preventing extubation failure (113 of 156) studies." | 5.30 | Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups. ( Kamath, A; Lewis, LES; M, S; Nayak, K; Purkayastha, J, 2019) |
| "Caffeine is effective in the treatment of apnea of prematurity." | 5.27 | Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018) |
| "Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively." | 5.27 | Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985) |
| " The mean plasma half-live of theophylline was 22." | 5.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 5.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity." | 5.24 | Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 5.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD." | 5.22 | Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022) |
| "Apnea of prematurity is a developmental disorder affecting most extremely preterm infants." | 5.22 | Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant. ( Bancalari, E; Chavez, L, 2022) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 5.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 5.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants." | 5.22 | [Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016) |
| "It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants." | 5.22 | Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016) |
| "• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years." | 5.20 | High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015) |
| "Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication." | 5.19 | The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014) |
| "This retrospective study reviewed weight gain, time to reach full feeds and time to cease caffeine in PBs previously enrolled in the RCT." | 5.19 | CeasIng Cpap At standarD criteriA (CICADA): impact on weight gain, time to full feeds and caffeine use. ( Abdel-Latif, ME; Broom, M; Shadbolt, B; Stewart, A; Todd, DA; Wright, A; Ying, L, 2014) |
| "Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system." | 5.19 | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 5.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial." | 5.14 | Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed." | 5.12 | Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 5.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 5.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "Preterm infants with a gestational age of <32 weeks and birth weight of <1,500 g were randomized to receive either caffeine or aminophylline treatment for apnea of prematurity." | 5.09 | Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. ( Bertini, G; Dani, C; Martelli, E; Reali, MF; Rubaltelli, FF; Tronchin, M; Wiechmann, L, 2000) |
| "Aminophylline and caffeine are commonly used for prophylaxis of apnea in premature infants." | 5.08 | Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. ( Brendstrup, L; Greisen, G; Larsen, PB; Lundstrøm, KE; Skov, L, 1995) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 5.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 5.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| " In the large international Caffeine for Apnea of Prematurity trial, caffeine improved survival without neurodevelopmental disability at 18 months and demonstrated long term safety up to 11 years." | 5.05 | Neurodevelopmental outcomes after neonatal caffeine therapy. ( Grunau, RE; Synnes, A, 2020) |
| "Caffeine is an effective treatment for apnea of prematurity and has several important benefits, including decreasing respiratory morbidity and motor impairment." | 5.05 | Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose? ( Patel, RM; Saroha, V, 2020) |
| "The Caffeine for Apnea of Prematurity (CAP) trial showed that caffeine was safe when used with standard dosing and provided both pulmonary and neurological benefits to preterm infants." | 5.05 | National and international guidelines for neonatal caffeine use: Are they evidenced-based? ( Eichenwald, EC, 2020) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 5.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 5.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| " While robust evidence supports the use of standard doses of caffeine for apnea of prematurity or to facilitate successful extubation, much remains unknown regarding the boundaries of efficacy and safety for this common therapeutic agent." | 5.01 | Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine. ( McPherson, C; Rostas, SE, 2019) |
| "Placebo-controlled trials have shown that caffeine is highly effective in treating apnoea of prematurity and reduces the risk of bronchopulmonary dysplasia (BPD) and neurodevelopmental impairment (NDI)." | 4.98 | High versus standard dose caffeine for apnoea: a systematic review. ( Hutten, GJ; Miedema, M; Onland, W; van Kaam, AH; Vliegenthart, R, 2018) |
| "Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants." | 4.98 | Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 4.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| " Despite aggressive respiratory support including mechanical ventilation, continuous positive airway pressure, oxygen and caffeine therapy to reduce apnea and accompanying intermittent hypoxemia, the incidence of intermittent hypoxemia events continues to increase during the first few months of life." | 4.93 | Cardiorespiratory events in preterm infants: interventions and consequences. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 4.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| " It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity." | 4.90 | Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014) |
| "Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems." | 4.87 | Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011) |
| "Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult." | 4.86 | [Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 4.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| " This ubiquitous trimethylxanthine, pervasively used in the human diet and beverages, significantly impacts on major acute neonatal morbidities including apnea of prematurity, bronchopulmonary dysplasia, patent ductus arteriousus with or without surgical ligation and post-operative apnea." | 4.86 | Caffeine impact on neonatal morbidities. ( Aranda, JV; Beharry, K; Davis, J; Natarajan, G; Valencia, GB, 2010) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates." | 4.81 | Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 4.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 4.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 4.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| " Caffeine is used for the treatment of apnea of prematurity and as an additive in several analgesics and migraine remedies, and as a panacea for hyperkinetic children." | 4.77 | Caffeine: a new look at an age-old drug. ( Gupta, P; Somani, SM, 1988) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 4.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity." | 4.12 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 4.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "Caffeine is routinely used in preterm infants for apnea of prematurity." | 4.12 | Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range? ( Aghai, ZH; Amendolia, B; Bhat, V; Chung, J; Nakhla, T; Saslow, J; Slater-Myer, L; Tran Lopez, K, 2022) |
| "Apnea of prematurity can persist despite caffeine therapy in preterm infants." | 4.02 | The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021) |
| "A frequent challenge in Neonatology is the high frequency of spontaneously occurring hypoxemic events, a majority of which are associated with apnea or hypoventilation." | 4.02 | Are we over-treating hypoxic spells in preterm infants? ( Conlon, S; Di Fiore, JM; Martin, RJ, 2021) |
| "Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity." | 3.96 | Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020) |
| "Caffeine to prevent or treat apnea of prematurity in the newborn period is now standard of care for infants born very preterm." | 3.96 | Childhood respiratory outcomes after neonatal caffeine therapy. ( Cheong, JLY; Doyle, LW, 2020) |
| " It appears that infants with apnea of prematurity and those receiving assisted ventilation are the most likely to benefit from caffeine." | 3.96 | When to start and stop caffeine and why respiratory status matters. ( Davis, PG, 2020) |
| "Caffeine is the preferred pharmacologic treatment for apnea of prematurity." | 3.96 | Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa. ( Ayede, AI; Ekhaguere, OA; Ezeaka, CV, 2020) |
| " High doses of caffeine may produce better control of apnea." | 3.96 | Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ( Aranda, JV; Beharry, KD, 2020) |
| "Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and assessed at the Royal Women's Hospital in Melbourne at 11 years of age had expiratory flow rates measured according to the standards of the American Thoracic Society." | 3.85 | Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth. ( Cheong, JLY; Doyle, LW; Ranganathan, S, 2017) |
| "Caffeine citrate is the treatment of choice for apnea of prematurity (AOP)." | 3.83 | The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study. ( Carnielli, VP; Fabbri, L; Ferrari, F; Kiechl-Kohlendorfer, U; Lasagna, G; Lista, G; Papagaroufalis, K; Polackova, R; Saenz, P, 2016) |
| " Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords." | 3.83 | [Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016) |
| " We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity." | 3.80 | Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014) |
| " Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis." | 3.79 | Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013) |
| "To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age." | 3.77 | Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011) |
| "Administration of caffeine citrate (caffeine) has been a central component of the treatment of apnea of prematurity." | 3.75 | Acute hemodynamic effects of caffeine administration in premature infants. ( Bin-Nun, A; Ionchev, A; Meadow, W; Soloveychik, V; Sriram, S, 2009) |
| "Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies." | 3.73 | [Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age." | 3.73 | [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| " This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea." | 3.71 | Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001) |
| "To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications." | 3.70 | Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000) |
| "Theophylline has been widely used to treat apnea of premature neonates." | 3.70 | Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ( Ahn, HW; Choi, JH; Park, KJ; Shin, WG; Suh, OK, 1999) |
| "Apnea of prematurity is a common problem in neonatal intensive care nurseries." | 3.68 | Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 3.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "Caffeine, used for treatment of idiopathic apnea in preterm infants, may have a vasoconstrictive effect on cerebral vessels." | 3.67 | Does caffeine affect cerebral blood flow in the preterm infant? ( Baan, J; Ruys, JH; Stijnen, T; Van Bel, F; Van de Bor, M, 1989) |
| "Administering caffeine citrate is a safe, noninvasive way to treat premature infants with persistent apnea." | 3.67 | Caffeine citrate in the NICU. ( Flood, E, 1989) |
| "Five neonates (4 premature) and 16 infants (6 prematurely born), 15-588 days old, received caffeine as citrate salt for apnea." | 3.67 | Developmental changes of caffeine elimination in infancy. ( Badoual, J; Carrier, O; d'Athis, P; Moran, C; Olive, G; Pons, G; Rey, E; Richard, MO, 1988) |
| "Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"." | 3.67 | [Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987) |
| "This review provides an understanding of current problems related to apnea of infancy." | 3.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| "The efficacy of low and high dose caffeine on idiopathic bradycardia and hypoxaemia was tested in premature infants." | 3.67 | [Effectiveness of low- and high-dose caffeine on idiopathic bradycardia and hypoxemia in premature infants]. ( Bucher, HU; Duc, G; Fallenstein, F; Mieth, D, 1985) |
| "The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea." | 3.66 | Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983) |
| "Simultaneous blood and saliva samples were drawn for determination of caffeine and theophylline concentrations in 17 infants receiving caffeine or theophylline therapy for apnea of prematurity." | 3.66 | Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. ( Bada, HS; Khanna, NN; Somani, SM, 1980) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 3.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule." | 3.66 | Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979) |
| "Plasma concentrations of theophylline and caffeine in seven premature neonates receiving theophylline orally for treatment of apnea at age one to 9 days were measured by high performance liquid chromatography, ultraviolet spectrophotometry, and mass spectrometry." | 3.66 | Metabolism of theophylline to caffeine in premature newborn infants. ( Aranda, JV; Baltassat, P; Bethenod, M; Bory, C; Frederich, A; Porthault, M, 1979) |
| "Caffeine treatment reduces the frequency of apnoea of prematurity (AOP) and eliminates the need for mechanical ventilation by acting as a nonspecific inhibitor of adenosine A1 and adenosine 2A receptors." | 2.77 | Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. ( Duman, N; Kumral, A; Ozkan, H; Tuzun, F; Yesilirmak, DC, 2012) |
| "If caffeine was found to have a greater effect, this would influence prescribing habits." | 2.69 | Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. ( Fang, S; Gamsu, HR; Greenough, A; Marsden, JT; Peters, TJ; Sherwood, RA, 1998) |
| " However, there are still uncertainties regarding effects on central nervous system development, time of discontinuation and dosing of the drug." | 2.52 | Caffeine for preterm infants: current indications and uncertainties. ( Carnielli, VP; Nobile, S, 2015) |
| "· Identification of risk factors for central apnea can lead to improved treatment protocols." | 1.62 | Central Apnea of Prematurity: Does Sex Matter? ( Fairchild, KD; Kuhn, L; Lake, DE; Moorman, JR; Nagraj, VP, 2021) |
| "Caffeine citrate was used in extremely premature infants at younger gestation, at higher doses, and for longer durations than recommended on the drug label." | 1.51 | Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. ( Bendel-Stenzel, E; Chhabra, R; Harper, B; Ku, L; Laughon, M; Moya, F; Payne, EH; Puia-Dumitrescu, M; Smith, PB; Soriano, A; Wade, KC; Zhao, J, 2019) |
| "51% had osteopenia of prematurity and 8% had spontaneous rib fractures." | 1.48 | Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study. ( Ali, E; Jiang, D; Moffatt, M; Narvey, M; Reed, M; Rockman-Greenberg, C, 2018) |
| " Further studies should focus on the timing and dosage of caffeine to optimize the prevention of AKI." | 1.48 | Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study. ( Askenazi, DJ; Boohaker, LJ; Carmody, JB; Charlton, JR; Griffin, RL; Guillet, R; Harer, MW; Selewski, DT; Swanson, JR, 2018) |
| "To identify dosing strategies that will assure stable caffeine concentrations in preterm neonates despite changing caffeine clearance during the first 8 weeks of life." | 1.46 | Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. ( Datta, AN; Jost, K; Koch, G; Pfister, M; Schulzke, SM; van den Anker, J, 2017) |
| " In conclusion, cisapride has a positive influence on GOR parameters during caffeine treatment without impairing the oral bioavailability or therapeutic effect of caffeine." | 1.31 | Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine. ( Baisch, HJ; Heimann, G; Kentrup, H; Kusenbach, G; Skopnik, H, 2000) |
| "Caffeine led to an increase in the mean arterial blood pressure on the first 3 days of therapy, but the heart rate did not change." | 1.28 | Cardiovascular effects of caffeine therapy in preterm infants. ( Erickson, R; Sims, ME; Walther, FJ, 1990) |
| "The symptoms of acute poisoning after accidental administration of ten times the usually prescribed dosage of caffeine in a premature infant included the following neurological signs: incessant tremors, hypertonia, continuous opisthotonos posture, whining and crying and digestive disturbances." | 1.27 | Treatment of caffeine intoxication by exchange transfusion in a newborn. ( Bonte, JB; Debruyne, D; Lacotte, J; Laloum, D; Moulin, M; Perrin, C, 1987) |
| "Caffeine was administered for 3." | 1.27 | Effect of caffeine on pneumogram and apnoea of infancy. ( Anwar, M; Graff, M; Hegyi, T; Hiatt, M; Mojica, N; Mondestin, H; Novo, R, 1986) |
| " Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established." | 1.27 | [Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986) |
| " The elevated blood caffeine levels in breast-fed infants was not related to higher daily dosage of caffeine citrate (4." | 1.27 | Delay in caffeine elimination in breast-fed infants. ( Billon, B; Le Guennec, JC, 1987) |
| "Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively." | 1.27 | Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985) |
| " The mean plasma half-live of theophylline was 22." | 1.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Caffeine was detectable in plasma at birth, and in preterm infants not receiving theophylline; plasma levels of caffeine tended to be similar to the levels in their mothers' milk." | 1.26 | Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ( Brazier, JL; Renaud, H; Ribon, B; Salle, BL, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (25.93) | 18.7374 |
| 1990's | 15 (7.94) | 18.2507 |
| 2000's | 28 (14.81) | 29.6817 |
| 2010's | 61 (32.28) | 24.3611 |
| 2020's | 36 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Saini, SS | 1 |
| Kumar, P | 1 |
| Ariagno, S | 1 |
| Thorvilson, M | 1 |
| Andersen, L | 1 |
| Collura, C | 1 |
| Wang, J | 1 |
| Xin, Y | 1 |
| Wei, Y | 1 |
| Zheng, R | 1 |
| McPherson, C | 2 |
| Lean, RE | 1 |
| Cyr, PEP | 1 |
| Inder, TE | 1 |
| Rogers, CE | 1 |
| Smyser, CD | 1 |
| Yuan, Y | 1 |
| Yang, Y | 1 |
| Lei, X | 1 |
| Dong, W | 1 |
| Yang, T | 1 |
| Shen, Q | 1 |
| Wang, S | 1 |
| Dong, T | 1 |
| Liang, L | 1 |
| Xu, F | 2 |
| He, Y | 1 |
| Li, C | 1 |
| Luo, F | 1 |
| Liang, J | 1 |
| Tang, C | 1 |
| Yang, J | 1 |
| Chavez, L | 1 |
| Bancalari, E | 2 |
| Xie, JB | 1 |
| Lin, XZ | 1 |
| Miao, Y | 1 |
| Zhou, Y | 1 |
| Zhao, S | 1 |
| Liu, W | 1 |
| Wang, A | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Jiang, H | 1 |
| García-Robles, A | 1 |
| Solaz-García, Á | 1 |
| Verdú-Andrés, J | 1 |
| Andrés, JLP | 1 |
| Cañada-Martínez, AJ | 1 |
| Pericás, CC | 1 |
| Ponce-Rodriguez, HD | 1 |
| Vento, M | 2 |
| González, PS | 1 |
| Prakash, R | 2 |
| Bruschettini, M | 3 |
| Brattström, P | 1 |
| Russo, C | 1 |
| Onland, W | 3 |
| Davis, PG | 8 |
| Soll, R | 1 |
| Schmidt, B | 10 |
| Maeda, T | 1 |
| Sekiguchi, K | 1 |
| Wasada, R | 1 |
| Ihara, K | 1 |
| Rostas, SE | 1 |
| Johansson, M | 2 |
| Juhl Jørgensen, K | 1 |
| Ji, D | 1 |
| Smith, PB | 2 |
| Clark, RH | 1 |
| Zimmerman, KO | 1 |
| Laughon, M | 2 |
| Ku, L | 2 |
| Greenberg, RG | 1 |
| Nylander Vujovic, S | 1 |
| Nava, C | 1 |
| Chung, J | 1 |
| Tran Lopez, K | 1 |
| Amendolia, B | 1 |
| Bhat, V | 1 |
| Nakhla, T | 1 |
| Slater-Myer, L | 1 |
| Saslow, J | 1 |
| Aghai, ZH | 1 |
| Ilhan, O | 1 |
| Bor, M | 1 |
| Alhersh, E | 1 |
| Abushanab, D | 1 |
| Al-Shaibi, S | 1 |
| Al-Badriyeh, D | 1 |
| Nagraj, VP | 1 |
| Lake, DE | 1 |
| Kuhn, L | 1 |
| Moorman, JR | 1 |
| Fairchild, KD | 1 |
| He, T | 1 |
| Liao, ZC | 1 |
| Ding, Y | 1 |
| Wang, MJ | 1 |
| Li, W | 1 |
| Gan, JM | 1 |
| Yue, SJ | 1 |
| Liu, S | 1 |
| Zhang, X | 2 |
| Liu, Y | 2 |
| Yuan, X | 1 |
| Yang, L | 1 |
| Zhang, R | 1 |
| Wang, X | 1 |
| Zhu, C | 1 |
| Guo, A | 1 |
| Zhu, Z | 1 |
| Xue, J | 1 |
| Di, X | 1 |
| Fan, J | 1 |
| Huang, L | 1 |
| Zhao, P | 1 |
| Hu, X | 1 |
| Xie, H | 1 |
| Synnes, A | 1 |
| Grunau, RE | 4 |
| Cheong, JLY | 2 |
| Doyle, LW | 11 |
| Saroha, V | 2 |
| Patel, RM | 2 |
| Eichenwald, EC | 1 |
| Ekhaguere, OA | 1 |
| Ayede, AI | 1 |
| Ezeaka, CV | 1 |
| Zupancic, JAF | 1 |
| Aranda, JV | 9 |
| Beharry, KD | 1 |
| Pournami, F | 1 |
| Prabhakar, J | 1 |
| Nandakumar, A | 1 |
| Nair, PMC | 1 |
| Jain, N | 1 |
| Engbers, AGJ | 1 |
| Völler, S | 1 |
| Poets, CF | 7 |
| Knibbe, CAJ | 1 |
| Reiss, IKM | 1 |
| Koch, BCP | 1 |
| Flint, RB | 1 |
| Simons, SHP | 1 |
| Conlon, S | 1 |
| Di Fiore, JM | 2 |
| Martin, RJ | 3 |
| Elmowafi, M | 1 |
| Mohsen, N | 1 |
| Nour, I | 2 |
| Nasef, N | 2 |
| Mohd Kori, AM | 1 |
| Van Rostenberghe, H | 1 |
| Ibrahim, NR | 1 |
| Yaacob, NM | 1 |
| Nasir, A | 1 |
| Roberts, RS | 9 |
| Anderson, PJ | 3 |
| Asztalos, EV | 3 |
| Costantini, L | 3 |
| Dewey, D | 2 |
| D'Ilario, J | 3 |
| Moddemann, D | 3 |
| Nelson, H | 2 |
| Ohlsson, A | 4 |
| Solimano, A | 4 |
| Tin, W | 5 |
| Shivakumar, M | 3 |
| Jayashree, P | 2 |
| Najih, M | 1 |
| Lewis, LES | 3 |
| Bhat Y, R | 1 |
| Kamath, A | 2 |
| Shashikala, - | 1 |
| Ranganathan, S | 1 |
| Dobson, NR | 3 |
| Rhein, LM | 2 |
| Darnall, RA | 2 |
| Corwin, MJ | 2 |
| Heeren, TC | 2 |
| Eichenwald, E | 1 |
| James, LP | 1 |
| McEntire, BL | 2 |
| Hunt, CE | 3 |
| deRegnier, RA | 1 |
| Koch, G | 1 |
| Datta, AN | 1 |
| Jost, K | 1 |
| Schulzke, SM | 1 |
| van den Anker, J | 1 |
| Pfister, M | 1 |
| O'Halloran, KD | 2 |
| McDonald, FB | 2 |
| Khurana, S | 1 |
| Sujith Kumar Reddy, GV | 1 |
| Ramesh Bhat, Y | 1 |
| Chalwadi, UK | 1 |
| Kalappanavar, NK | 1 |
| Simon Lewis, LE | 1 |
| Ali, E | 1 |
| Rockman-Greenberg, C | 1 |
| Moffatt, M | 1 |
| Narvey, M | 1 |
| Reed, M | 1 |
| Jiang, D | 1 |
| Vliegenthart, R | 1 |
| Miedema, M | 1 |
| Hutten, GJ | 1 |
| van Kaam, AH | 2 |
| Dix, LML | 1 |
| van Bel, F | 2 |
| Baerts, W | 1 |
| Lemmers, PMA | 1 |
| Harer, MW | 1 |
| Askenazi, DJ | 1 |
| Boohaker, LJ | 1 |
| Carmody, JB | 1 |
| Griffin, RL | 1 |
| Guillet, R | 1 |
| Selewski, DT | 1 |
| Swanson, JR | 1 |
| Charlton, JR | 1 |
| Mürner-Lavanchy, IM | 1 |
| Dong, WB | 1 |
| Dempsey, EM | 1 |
| M, S | 1 |
| Nayak, K | 1 |
| Purkayastha, J | 1 |
| Álvarado Socarras, JL | 1 |
| Jain, VG | 1 |
| Jobe, A | 1 |
| Puia-Dumitrescu, M | 1 |
| Zhao, J | 1 |
| Soriano, A | 1 |
| Payne, EH | 1 |
| Harper, B | 1 |
| Bendel-Stenzel, E | 1 |
| Moya, F | 1 |
| Chhabra, R | 1 |
| Wade, KC | 1 |
| Kumar, M | 1 |
| Chawla, R | 1 |
| Haloi, P | 1 |
| Singh, M | 1 |
| Abu Jawdeh, EG | 1 |
| O'Riordan, M | 1 |
| Limrungsikul, A | 1 |
| Bandyopadhyay, A | 1 |
| Argus, BM | 1 |
| Nakad, PE | 1 |
| Supapannachart, S | 1 |
| Yunis, KA | 1 |
| Vatlach, S | 1 |
| Arand, J | 1 |
| Engel, C | 1 |
| Schoen, K | 1 |
| Yu, T | 1 |
| Stockmann, C | 1 |
| Spigarelli, MG | 1 |
| Sherwin, CM | 1 |
| Ulanovsky, I | 1 |
| Haleluya, NS | 1 |
| Blazer, S | 1 |
| Weissman, A | 1 |
| Broom, M | 1 |
| Ying, L | 1 |
| Wright, A | 1 |
| Stewart, A | 1 |
| Abdel-Latif, ME | 1 |
| Shadbolt, B | 1 |
| Todd, DA | 1 |
| Curstedt, T | 1 |
| Halliday, HL | 1 |
| Hallman, M | 1 |
| Saugstad, OD | 1 |
| Speer, CP | 1 |
| Kreutzer, K | 1 |
| Bassler, D | 1 |
| Marcus, CL | 2 |
| Meltzer, LJ | 1 |
| Traylor, J | 1 |
| Dix, J | 1 |
| Asztalos, E | 2 |
| Opie, G | 1 |
| Biggs, SN | 1 |
| Nixon, GM | 2 |
| Narang, I | 1 |
| Bhattacharjee, R | 1 |
| Davey, M | 1 |
| Horne, RS | 1 |
| Cheshire, M | 1 |
| Gibbons, J | 1 |
| Bradford, R | 1 |
| Khan, SR | 1 |
| Araujo, P | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Mohammed, S | 1 |
| Shabaan, AE | 1 |
| Shouman, B | 1 |
| Abdel-Hady, H | 1 |
| Nobile, S | 1 |
| Carnielli, VP | 2 |
| Gauda, E | 1 |
| MacFarlane, P | 1 |
| Zhao, Y | 1 |
| Tian, X | 1 |
| Liu, G | 1 |
| Lista, G | 1 |
| Fabbri, L | 1 |
| Polackova, R | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Papagaroufalis, K | 1 |
| Saenz, P | 1 |
| Ferrari, F | 1 |
| Lasagna, G | 1 |
| Armanian, AM | 1 |
| Iranpour, R | 1 |
| Faghihian, E | 1 |
| Salehimehr, N | 1 |
| Chen, C | 1 |
| Shu, XX | 1 |
| Yang, XY | 1 |
| Shi, J | 1 |
| Tang, J | 1 |
| Mu, DZ | 1 |
| Vliegenthart, RJ | 1 |
| Ten Hove, CH | 1 |
| Maheux, A | 1 |
| Pladys, P | 1 |
| Laviolle, B | 1 |
| Soloveychik, V | 1 |
| Bin-Nun, A | 1 |
| Ionchev, A | 1 |
| Sriram, S | 1 |
| Meadow, W | 1 |
| Skouroliakou, M | 1 |
| Bacopoulou, F | 1 |
| Markantonis, SL | 1 |
| Haslam, R | 1 |
| Sinha, S | 1 |
| Moriette, G | 3 |
| Lescure, S | 1 |
| El Ayoubi, M | 1 |
| Lopez, E | 1 |
| Henderson-Smart, DJ | 10 |
| Steer, PA | 2 |
| Winckworth, LC | 1 |
| Powell, E | 1 |
| Beharry, K | 1 |
| Valencia, GB | 1 |
| Natarajan, G | 1 |
| Davis, J | 1 |
| Mathew, OP | 1 |
| De Paoli, AG | 2 |
| Dukhovny, D | 1 |
| Lorch, SA | 1 |
| Kok, JH | 1 |
| Kamholz, KL | 1 |
| Wang, N | 1 |
| Mao, W | 1 |
| Zupancic, JA | 1 |
| Davis, P | 3 |
| Kumral, A | 1 |
| Tuzun, F | 1 |
| Yesilirmak, DC | 1 |
| Duman, N | 1 |
| Ozkan, H | 1 |
| Cesar, K | 1 |
| Iolster, T | 1 |
| White, D | 1 |
| Latifi, S | 1 |
| Picone, S | 1 |
| Bedetta, M | 1 |
| Paolillo, P | 1 |
| McNamara, DG | 1 |
| Anderson, BJ | 1 |
| Marlier, L | 1 |
| Gaugler, C | 1 |
| Messer, J | 1 |
| Vermeylen, D | 1 |
| Franco, P | 1 |
| Hennequin, Y | 1 |
| Pardou, A | 1 |
| Brugmans, M | 1 |
| Simon, P | 1 |
| Hassid, S | 1 |
| Barrington, KJ | 2 |
| Ducrocq, S | 2 |
| Biran-Mucignat, V | 2 |
| Lebas, F | 2 |
| Baudon, JJ | 2 |
| Gold, F | 2 |
| Boelle, PY | 1 |
| Coulter, DM | 1 |
| Hand, IL | 1 |
| Noble, LM | 1 |
| Stevenson, DK | 1 |
| Haley, TJ | 1 |
| Sourgens, H | 1 |
| Staib, AH | 1 |
| Bielicki, M | 1 |
| von Loewenich, V | 1 |
| Outerbridge, EW | 2 |
| Trippenbach, T | 1 |
| Edwards, RC | 1 |
| Voegeli, CJ | 1 |
| Lönnerholm, G | 2 |
| Lindström, B | 2 |
| Paalzow, L | 1 |
| Sedin, G | 1 |
| Hargreaves, DB | 1 |
| Lealman, GT | 1 |
| Mulley, BA | 1 |
| Gorodischer, R | 1 |
| Karplus, M | 1 |
| Khanna, NN | 4 |
| Somani, SM | 5 |
| Boyer, A | 1 |
| Miller, J | 1 |
| Chua, C | 1 |
| Menke, JA | 1 |
| Berthou, F | 1 |
| Alix, D | 1 |
| Riche, C | 1 |
| Picart, D | 1 |
| Dreano, Y | 1 |
| Gouedard, H | 1 |
| Bada, HS | 3 |
| Murat, I | 2 |
| Blin, MC | 1 |
| Couchard, M | 1 |
| Flouvat, B | 2 |
| De Gamarra, E | 2 |
| Relier, JP | 2 |
| Dreyfus-Brisac, C | 1 |
| Riechert, M | 2 |
| Lipowsky, G | 1 |
| Stöckl, H | 1 |
| Stiegler, H | 1 |
| Floberg, S | 1 |
| Lundstrøm, KE | 1 |
| Larsen, PB | 2 |
| Brendstrup, L | 2 |
| Skov, L | 2 |
| Greisen, G | 1 |
| Flachs, H | 1 |
| Sankaran, K | 1 |
| Hindmarsh, KW | 1 |
| Tan, L | 1 |
| Kalapurackal, M | 1 |
| Sidhu, J | 1 |
| Triggs, E | 1 |
| Charles, B | 1 |
| Tudehope, D | 1 |
| Gray, P | 1 |
| Cowley, D | 1 |
| Duc, G | 3 |
| Bucher, HU | 3 |
| Calhoun, LK | 1 |
| Laubscher, B | 1 |
| Greenough, A | 2 |
| Dimitriou, G | 1 |
| Fang, S | 1 |
| Sherwood, RA | 1 |
| Gamsu, HR | 1 |
| Marsden, JT | 1 |
| Peters, TJ | 1 |
| Darraj, S | 1 |
| Bohnhorst, B | 1 |
| Kentrup, H | 1 |
| Baisch, HJ | 1 |
| Kusenbach, G | 2 |
| Heimann, G | 1 |
| Skopnik, H | 1 |
| Subhani, M | 1 |
| Katz, S | 1 |
| DeCristofaro, JD | 1 |
| Steer, P | 4 |
| Ahn, HW | 1 |
| Shin, WG | 1 |
| Park, KJ | 1 |
| Suh, OK | 1 |
| Choi, JH | 1 |
| Dani, C | 1 |
| Bertini, G | 1 |
| Reali, MF | 1 |
| Tronchin, M | 1 |
| Wiechmann, L | 1 |
| Martelli, E | 1 |
| Rubaltelli, FF | 1 |
| Bhatia, J | 1 |
| Bauer, J | 1 |
| Maier, K | 1 |
| Linderkamp, O | 1 |
| Hentschel, R | 1 |
| Bahi, N | 1 |
| Nehlig, A | 1 |
| Evrard, P | 1 |
| Gressens, P | 1 |
| Aggarwal, R | 1 |
| Singhal, A | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Gannon, BA | 1 |
| Bory, C | 2 |
| Baltassat, P | 2 |
| Porthault, M | 2 |
| Bethenod, M | 2 |
| Frederich, A | 2 |
| Boutroy, MJ | 3 |
| Vert, P | 4 |
| Monin, P | 2 |
| Royer, RJ | 2 |
| Royer-Morrot, MJ | 2 |
| Gunn, TR | 1 |
| Metrakos, K | 1 |
| Riley, P | 1 |
| Willis, D | 1 |
| Turmen, T | 2 |
| Cook, CE | 1 |
| Gorman, W | 1 |
| Collinge, JM | 1 |
| Loughnan, PM | 1 |
| Aldridge, A | 1 |
| Neims, AH | 1 |
| Brazier, JL | 1 |
| Renaud, H | 1 |
| Ribon, B | 1 |
| Salle, BL | 1 |
| Tin, AA | 1 |
| Louridas, TA | 1 |
| Lucey, JF | 1 |
| Romagnoli, C | 1 |
| De Carolis, MP | 1 |
| Muzii, U | 1 |
| Zecca, E | 1 |
| Tortorolo, G | 1 |
| Chiarotti, M | 1 |
| De Giovanni, N | 1 |
| Carnevale, A | 1 |
| van den Anker, JN | 1 |
| Jongejan, HT | 1 |
| Sauer, PJ | 1 |
| Aujard, Y | 1 |
| Morisot, C | 1 |
| Simoens, C | 1 |
| Trublin, F | 1 |
| Lhermitte, M | 2 |
| Gremillet, C | 1 |
| Robert, MH | 1 |
| Lequien, P | 2 |
| Walther, FJ | 1 |
| Erickson, R | 1 |
| Sims, ME | 1 |
| Van de Bor, M | 1 |
| Stijnen, T | 1 |
| Baan, J | 1 |
| Ruys, JH | 1 |
| Flood, E | 1 |
| Noerr, B | 1 |
| Bairam, A | 2 |
| Cattarossi, L | 1 |
| Colacino, V | 1 |
| Janes, A | 1 |
| LoGreco, P | 1 |
| Rubini, S | 1 |
| Zilli, M | 1 |
| Macagno, F | 1 |
| Gupta, P | 1 |
| Pons, G | 1 |
| Carrier, O | 1 |
| Richard, MO | 1 |
| Rey, E | 1 |
| d'Athis, P | 1 |
| Moran, C | 1 |
| Badoual, J | 1 |
| Olive, G | 1 |
| Badonnel, Y | 1 |
| Houdret, N | 1 |
| Broly, F | 1 |
| Roussel, P | 1 |
| Carpentier, C | 1 |
| Zaoui, C | 1 |
| Sacré, L | 1 |
| Vandenplas, Y | 1 |
| Perrin, C | 1 |
| Debruyne, D | 1 |
| Lacotte, J | 1 |
| Laloum, D | 1 |
| Bonte, JB | 1 |
| Moulin, M | 1 |
| Spitzer, AR | 1 |
| Fox, WW | 1 |
| Anwar, M | 1 |
| Mondestin, H | 1 |
| Mojica, N | 1 |
| Novo, R | 1 |
| Graff, M | 1 |
| Hiatt, M | 1 |
| Hegyi, T | 1 |
| Reinhardt, D | 1 |
| Le Guennec, JC | 2 |
| Billon, B | 2 |
| Fallenstein, F | 1 |
| Mieth, D | 1 |
| Brouard, C | 1 |
| Pajot, N | 1 |
| Walti, H | 1 |
| Paré, C | 1 |
| Vorherr, H | 1 |
| Koppe, JG | 1 |
| Rietveld, HJ | 1 |
| de Wilde, TW | 1 |
| Subić, M | 1 |
| Subic-Cerneka, Z | 1 |
| Schiff, D | 1 |
| Chan, G | 1 |
| Stern, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Intermittent Hypoxia and Caffeine in Infants Born Preterm (ICAF)[NCT03321734] | Phase 2 | 170 participants (Actual) | Interventional | 2019-01-18 | Completed | ||
| Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates[NCT02443389] | 2,186 participants (Actual) | Observational [Patient Registry] | 2015-03-31 | Completed | |||
| Pilot Study of Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm[NCT01875159] | Phase 3 | 98 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| High Versus Low Dose Caffeine as Respiratory Stimulant in Preterm Infants[NCT04144712] | Phase 1 | 80 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| Apneic Oxygenation to Prevent Oxygen Desaturation During Intubation in the NICU[NCT05451953] | 110 participants (Anticipated) | Interventional | 2022-07-21 | Recruiting | |||
| Effect of Early Use of Caffeine Citrate in Preterm Neonates Needing Respiratory Support.[NCT04001712] | Phase 3 | 54 participants (Actual) | Interventional | 2019-04-05 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Caffeine for Late Preterm Infants: A Double Blind Randomized Controlled Trial[NCT06026163] | Phase 2/Phase 3 | 134 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| WAVE Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability[NCT04528030] | 17 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | |||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia[NCT04447989] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | ||
| Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants[NCT02293824] | 50 participants (Anticipated) | Observational | 2014-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of episodes of Intermittent hypoxia per hour of pulse oximeter recording less than 90% oxygen saturation (NCT01875159)
Timeframe: 35, 36, 37, 38 weeks postmenstrual age
| Intervention | Events per hour (Mean) | |||
|---|---|---|---|---|
| Week 35 | Week 36 | Week 37 | Week 38 | |
| Active Comparator: no Caffeine | 8.4 | 8.2 | 5.2 | 4.7 |
| Caffeine | 3.6 | 3.8 | 4.3 | 4.2 |
Number of seconds of Intermittent hypoxia per hour of pulse oximeter recording less than 90% oxygen saturation (NCT01875159)
Timeframe: 35, 36, 37, 38 weeks postmenstrual age
| Intervention | seconds per hour (Mean) | |||
|---|---|---|---|---|
| Week 35 | Week 36 | Week 37 | Week 38 | |
| Active Comparator: no Caffeine | 106.3 | 100.1 | 66.8 | 66.0 |
| Caffeine | 50.9 | 49.5 | 58.8 | 69.3 |
46 reviews available for caffeine and Infant, Premature, Diseases
| Article | Year |
|---|---|
Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; In | 2022 |
Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2022 |
[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.
Topics: Aminophylline; Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases | 2022 |
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Humans; Infant; Infant, Extremely Premature; Inf | 2023 |
Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine.
Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System; Central Nervous System Stimulants; Dose- | 2019 |
Confounding biases in studies on early- versus late-caffeine in preterm infants: a systematic review.
Topics: Apnea; Caffeine; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infant, Premature; I | 2020 |
Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive | 2020 |
Neurodevelopmental outcomes after neonatal caffeine therapy.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; D | 2020 |
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Dose-Response Relationsh | 2020 |
National and international guidelines for neonatal caffeine use: Are they evidenced-based?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Evidence-Based Medicine; Humans; Infan | 2020 |
Cost-effectiveness and pricing of caffeine.
Topics: Caffeine; Citrates; Cost Control; Cost-Benefit Analysis; Drug Costs; Humans; Infant, Newborn; Infant | 2020 |
High versus standard dose caffeine for apnoea: a systematic review.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Dose-Response Relati | 2018 |
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot | 2018 |
[Preventive effect of caffeine on bronchopulmonary dysplasia in preterm infants].
Topics: Animals; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Premature; Infant, Premature, Disease | 2018 |
Is early caffeine therapy safe and effective for ventilated preterm infants?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2019 |
Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Drug Monitoring; Humans; Infant, Prema | 2014 |
Caffeine for apnea of prematurity: a neonatal success story.
Topics: Animals; Apnea; Birth Weight; Caffeine; Cost-Benefit Analysis; Drug Costs; Gestational Age; Humans; | 2014 |
Caffeine for preterm infants: current indications and uncertainties.
Topics: Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2015 |
Cardiorespiratory events in preterm infants: interventions and consequences.
Topics: Animals; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Continuous Positive Airway | 2016 |
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2017 |
[Apnea of prematurity: what's new?].
Topics: Apnea; Bradycardia; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Caffeine; Central Nervous Sys | 2010 |
Interventions for apnoea of prematurity: a personal view.
Topics: Amino Acids; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, | 2010 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2010 |
Question 1 Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Developmental Disabilities; | 2010 |
Caffeine impact on neonatal morbidities.
Topics: Animals; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premat | 2010 |
Apnea of prematurity: pathogenesis and management strategies.
Topics: Apnea; Arrhythmias, Cardiac; Brain Stem; Caffeine; Central Nervous System Stimulants; Continuous Pos | 2011 |
Methylxanthine treatment for apnoea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2010 |
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Humans; Hypoxia; Infant, Newborn; I | 2010 |
Caffeine citrate: when and for how long. A literature review.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Infant, Newborn; Infant, Prema | 2012 |
Prophylactic methylxanthines for extubation in preterm infants.
Topics: Caffeine; Central Nervous System Agents; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu | 2003 |
Methylxanthines for the treatment of apnea associated with bronchiolitis and anesthesia.
Topics: Anesthesia, General; Apnea; Bronchiolitis; Caffeine; Clinical Trials as Topic; Humans; Infant; Infan | 2004 |
Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults.
Topics: Adult; Age Factors; Apnea; Asthma; Biotransformation; Bradycardia; Caffeine; Child; Female; Half-Lif | 1983 |
Pharmacologic management of apnea of prematurity.
Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature, | 1996 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2000 |
Postoperative caffeine for preventing apnea in preterm infants.
Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In | 2000 |
Prophylactic methylxanthine for extubation in preterm infants.
Topics: Caffeine; Central Nervous System Agents; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2000 |
Current options in the management of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2001 |
Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants.
Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In | 2001 |
Apnea in the newborn.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; In | 2001 |
Theophylline or caffeine: which is best for apnea of prematurity?
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2000 |
Methylxanthines in apnea of prematurity.
Topics: Apnea; Caffeine; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Respi | 1979 |
Caffeine: a new look at an age-old drug.
Topics: Apnea; Arteriosclerosis; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Neoplasms | 1988 |
Drug excretion in breast milk.
Topics: Anti-Bacterial Agents; Barbiturates; Biological Transport, Active; Breast; Breast Feeding; Caffeine; | 1974 |
35 trials available for caffeine and Infant, Premature, Diseases
| Article | Year |
|---|---|
Five-year outcomes of premature infants randomized to high or standard loading dose caffeine.
Topics: Caffeine; Child; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Dise | 2022 |
[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial].
Topics: Apnea; Caffeine; Citrates; Double-Blind Method; Humans; Infant; Infant, Newborn; Infant, Premature; | 2020 |
Early application of caffeine improves white matter development in very preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child Development; Diffusion Tensor Imaging; Fem | 2020 |
Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu | 2021 |
Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Ox | 2022 |
A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2021 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
Topics: Aminophylline; Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 2017 |
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities; | 2017 |
Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child; Child Development; Double-Blind Method; F | 2018 |
Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups.
Topics: Aminophylline; Apnea; Caffeine; Dose-Response Relationship, Drug; Echocardiography; Female; Gestatio | 2019 |
Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial.
Topics: Caffeine; Central Nervous System Stimulants; Female; Gestational Age; Humans; Hypoxia; Infant, Newbo | 2014 |
Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial.
Topics: Caffeine; Central Nervous System Stimulants; Female; Gestational Age; Humans; Hypoxia; Infant, Newbo | 2014 |
Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial.
Topics: Caffeine; Central Nervous System Stimulants; Female; Gestational Age; Humans; Hypoxia; Infant, Newbo | 2014 |
Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial.
Topics: Caffeine; Central Nervous System Stimulants; Female; Gestational Age; Humans; Hypoxia; Infant, Newbo | 2014 |
The effects of caffeine on heart rate variability in newborns with apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Heart Rate; Humans; Infant, Newborn; Inf | 2014 |
CeasIng Cpap At standarD criteriA (CICADA): impact on weight gain, time to full feeds and caffeine use.
Topics: Apgar Score; Birth Weight; Caffeine; Continuous Positive Airway Pressure; Drug Administration Schedu | 2014 |
Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.
Topics: Actigraphy; Apnea; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Double-Blin | 2014 |
High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial.
Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relat | 2015 |
[Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants].
Topics: Apnea; Birth Weight; Caffeine; Citrates; Female; Gestational Age; Humans; Infant, Newborn; Infant, P | 2016 |
Caffeine Administration to Prevent Apnea in Very Premature Infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Female; Gestational Age; Hu | 2016 |
Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Drug Therapy, Combination | 2009 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity.
Topics: Bronchopulmonary Dysplasia; Caffeine; Case-Control Studies; Citrates; Drug Administration Schedule; | 2012 |
Olfactory stimulation prevents apnea in premature newborns.
Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The | 2005 |
Laryngeal oedema in neonatal apnoea and bradycardia syndrome (a pilot study).
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Bradycardia; Caffeine; De | 2005 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Prospective Studies; Recurren | 1981 |
Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline.
Topics: Aminophylline; Analysis of Variance; Apnea; Caffeine; Cerebrovascular Circulation; Humans; Infant, N | 1995 |
Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates.
Topics: Apnea; Bradycardia; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Prematur | 1995 |
Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants.
Topics: Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, | 1998 |
Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.
Topics: Anemia; Apnea; Caffeine; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu | 1998 |
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo | 1999 |
Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment.
Topics: Aminophylline; Apnea; Birth Weight; Blood Flow Velocity; Blood Volume; Caffeine; Central Nervous Sys | 2000 |
Does caffeine prevent hypoxaemic episodes in premature infants? A randomized controlled trial.
Topics: Blood Gas Monitoring, Transcutaneous; Bradycardia; Caffeine; Citrates; Clinical Trials as Topic; Dou | 1988 |
Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant.
Topics: Apnea; Caffeine; Double-Blind Method; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseas | 1987 |
Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline | 1985 |
108 other studies available for caffeine and Infant, Premature, Diseases
| Article | Year |
|---|---|
Caffeine Duration for Apnea of Prematurity: All Bets Are Off!
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2021 |
Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant; Infant, Newborn; Infant, | 2022 |
Effects of caffeine citrate on respiratory mechanics and pulmonary function during peri-extubation in premature infants with low body weight.
Topics: Airway Extubation; Body Weight; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Prematu | 2022 |
Risk factors that affect the degree of bronchopulmonary dysplasia in very preterm infants: a 5-year retrospective study.
Topics: Adult; Aminophylline; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Ductus Arteriosus, Patent; | 2022 |
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
It is time for a rethink about caffeine therapy for apnoea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Caffeine for Apnea of Prematurity: Too Much or Too Little of a Good Thing.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Caffeine not associated with irritable behaviour in very low-birth-weight infants.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Female; Hu | 2019 |
Is earlier better when it comes giving caffeine to preterm infants or are we risking unnecessary treatment and serious harm?
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2020 |
Wide variation in caffeine discontinuation timing in premature infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Cohort Studies; Combined Modality Ther | 2020 |
Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range?
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Re | 2022 |
Effects of Single Loading Dose of Intravenous Caffeine on Cerebral Oxygenation in Preterm Infants.
Topics: Brain; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Central Apnea of Prematurity: Does Sex Matter?
Topics: Bradycardia; Caffeine; Cohort Studies; Female; Gestational Age; Humans; Infant, Newborn; Infant, Pre | 2021 |
Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea.
Topics: Apnea; Asian People; Caffeine; Central Nervous System Stimulants; Citrates; Female; Humans; Infant, | 2020 |
Childhood respiratory outcomes after neonatal caffeine therapy.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Child; Citrates; Duc | 2020 |
When to start and stop caffeine and why respiratory status matters.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Hypoxia; Infant; Infant, Newbo | 2020 |
Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa.
Topics: Africa South of the Sahara; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Costs and | 2020 |
Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Huma | 2020 |
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Are we over-treating hypoxic spells in preterm infants?
Topics: Apnea; Caffeine; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Dis | 2021 |
Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Female; Follow-Up Studies; Humans; Infant, Newbo | 2017 |
Caffeine decreases intermittent hypoxia in preterm infants nearing term-equivalent age.
Topics: Adult; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Citrates; Drug Administrat | 2017 |
Dosing wisely: caffeine and the preterm infant.
Topics: Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2017 |
Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationsh | 2017 |
Pharmacotherapies for apnoea of prematurity: time to pause and consider targeted sex-specific strategies?
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 2018 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns.
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2017 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns: Author's Reply.
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2017 |
Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study.
Topics: Bone Diseases, Metabolic; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Newbo | 2018 |
Effects of caffeine on the preterm brain: An observational study.
Topics: Apnea; Brain; Caffeine; Electroencephalography; Gestational Age; Humans; Infant, Newborn; Infant, Pr | 2018 |
Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study.
Topics: Acute Kidney Injury; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature, Disease | 2018 |
Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study.
Topics: Acute Kidney Injury; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature, Disease | 2018 |
Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study.
Topics: Acute Kidney Injury; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature, Disease | 2018 |
Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study.
Topics: Acute Kidney Injury; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature, Disease | 2018 |
Caffeine therapy for apnoea of prematurity: Wake up to the fact that sex matters.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Sex Ch | 2018 |
Caffeine use in preterm infants: from magic to uncertainty.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2018 |
Self-reported Quality of Life at Middle School Age in Survivors of Very Preterm Birth: Results From the Caffeine for Apnea of Prematurity Trial.
Topics: Apnea; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Child; Female; Follow-Up S | 2019 |
Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Ductus Arteriosus, Paten | 2019 |
The use of caffeine for the treatment of apnea of prematurity and bradycardia in a holoprosencephalic child with cleft lip and palate.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Citrates; Cleft Lip; Cleft Palate; | 2013 |
Methylxanthine use for apnea of prematurity among an international cohort of neonatologists.
Topics: Apnea; Australia; Caffeine; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; | 2013 |
Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity.
Topics: Apnea; Caffeine; Chemistry, Pharmaceutical; Citrates; Drug-Related Side Effects and Adverse Reaction | 2014 |
More about surfactant, oxygen, caffeine and chronic lung disease.
Topics: Animals; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen Inhalation Therapy; | 2014 |
Former preterm infants, caffeine was good for you, but now beware of snoring!
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Reply: neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Europe; Female; Humans; Infant, Newborn; Infa | 2016 |
[Current research status of drug therapy for apnea of prematurity].
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2016 |
Caffeine for apnea in bronchiolitis.
Topics: Apnea; Bronchiolitis; Caffeine; Humans; Infant, Premature; Infant, Premature, Diseases | 2017 |
Acute hemodynamic effects of caffeine administration in premature infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Hemodynamics; Humans; Infant, Newborn; | 2009 |
Economic evaluation of caffeine for apnea of prematurity.
Topics: Apnea; Caffeine; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Infant, Premature, Diseases | 2011 |
Archimedes: Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2011 |
Caffeine as treatment for bronchiolitis-related apnoea.
Topics: Apnea; Bronchiolitis; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2012 |
Caffeine for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newb | 2006 |
[Caffeine citrate utilization for treatment of apnea in French neonatal units].
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Drug | 2006 |
[Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate].
Topics: Ambulatory Care; Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Continu | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Diuresis; Growth; Humans; Infant, Low Birth Weig | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, P | 2006 |
On the caffeination of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2007 |
T4 levels in methylxanthine-treated premature newborns.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Theoph | 1983 |
Interaction of caffeine and continuous distending airway pressure in neonatal apnea.
Topics: Apnea; Caffeine; Combined Modality Therapy; Humans; Infant, Newborn; Infant, Premature, Diseases; Lu | 1983 |
Inadvisability of using caffeine and sodium benzoate in neonates.
Topics: Benzoates; Benzoic Acid; Caffeine; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Di | 1984 |
Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.
Topics: Apnea; Caffeine; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1983 |
Plasma xanthine levels in premature infants treated for apnoea with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Xanth | 1983 |
Pharmacokinetic aspects of caffeine in premature infants with apnoea.
Topics: Apnea; Caffeine; Female; Half-Life; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Ki | 1982 |
Cross validation of serum to saliva relationships of caffeine, theophylline and total methylxanthines in neonates.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Saliva; Theophylline; Xanthin | 1982 |
[Use of caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Time | 1982 |
Caffeine and theophylline: serum/CSF correlation in premature infants.
Topics: Apnea; Blood-Brain Barrier; Caffeine; Chromatography, Liquid; Humans; Infant, Newborn; Infant, Prema | 1980 |
[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Protein Binding; Th | 1981 |
Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Regression Analysis; Saliva; | 1980 |
Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.
Topics: Alkylation; Apnea; Caffeine; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn; Infant, | 1980 |
Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity.
Topics: Apnea; beta-Endorphin; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthine; Xan | 1993 |
Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach.
Topics: Aminophylline; Apnea; Caffeine; Electric Impedance; Female; Humans; Infant, Newborn; Infant, Prematu | 1993 |
Aminophylline versus caffeine citrate...
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Cardiotonic Agents; Citrates; Clinical Trials as Topic; | 1995 |
Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine.
Topics: Caffeine; Cisapride; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hydrogen-Ion Concentr | 2000 |
Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature; Infant, Pr | 2000 |
Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
Topics: Aminophylline; Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Inf | 1999 |
Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea.
Topics: Apnea; Body Weight; Caffeine; Energy Metabolism; Humans; Infant, Newborn; Infant, Premature, Disease | 2001 |
Caffeine does not affect excitotoxic brain lesions in newborn mice.
Topics: Animals; Animals, Newborn; Caffeine; Cerebral Ventricles; Female; Humans; Infant, Newborn; Infant, P | 2001 |
Biotransformation of theophylline to caffeine in premature newborn.
Topics: Administration, Oral; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature | 1978 |
Methylation of theophylline to caffeine in premature infants.
Topics: Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Methylatio | 1979 |
Sequelae of caffeine treatment in preterm infants with apnea.
Topics: Apnea; Caffeine; Child Development; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Inf | 1979 |
Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.
Topics: Administration, Oral; Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseas | 1979 |
Plasma xanthine levels in low birthweight infants treated or not treated with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Metabolic Clearance Rate; Mil | 1979 |
Interconversion of theophylline and caffeine in newborn infants.
Topics: Age Factors; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Disease | 1979 |
Metabolism of theophylline to caffeine in premature newborn infants.
Topics: Adult; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; The | 1979 |
Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant.
Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophyl | 1979 |
Relationship of plasma and CSF concentrations of caffeine in neonates with apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases | 1979 |
Micro-method for the determination of caffeine and theophylline allowing direct application of biological fluids to thin-layer chromatography plates.
Topics: Apnea; Caffeine; Child; Child, Preschool; Chromatography, Thin Layer; Female; Humans; Infant; Infant | 1978 |
The xanthine treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Di | 1975 |
Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants.
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Caffeine; Humans; Infant, Newborn; Infa | 1992 |
Severe caffeine intoxication in a preterm neonate.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Male | 1992 |
[Caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases | 1990 |
[Efficacy of percutaneous caffeine in the treatment of apnea in the premature infant].
Topics: Administration, Cutaneous; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Ma | 1990 |
Cardiovascular effects of caffeine therapy in preterm infants.
Topics: Apnea; Blood Pressure; Caffeine; Cardiac Output; Heart; Heart Rate; Humans; Infant, Newborn; Infant, | 1990 |
Does caffeine affect cerebral blood flow in the preterm infant?
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Caffeine; Cerebrovascular Circulation; Humans; Infant; | 1989 |
Caffeine citrate in the NICU.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases; | 1989 |
Caffeine citrate. Pointers in practical pharmacology.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases | 1989 |
Low-dose doxapram for apnoea of prematurity.
Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di | 1986 |
Oral versus intramuscular loading of caffeine in idiopathic apnoea of prematurity.
Topics: Administration, Oral; Apnea; Blood Glucose; Caffeine; Humans; Infant, Newborn; Infant, Premature, Di | 1988 |
Developmental changes of caffeine elimination in infancy.
Topics: Aging; Apnea; Caffeine; Drug Administration Schedule; Gestational Age; Half-Life; Humans; Infant; In | 1988 |
Simultaneous administration of caffeine and phenobarbitone in infants with apnea.
Topics: Apnea; Caffeine; Drug Therapy, Combination; Half-Life; Humans; Infant; Infant, Newborn; Infant, Prem | 1987 |
[Xanthines in apnea of premature infants. Influence on gastroesophageal reflux].
Topics: Apnea; Caffeine; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature, Diseases; Xant | 1987 |
Treatment of caffeine intoxication by exchange transfusion in a newborn.
Topics: Acute Disease; Caffeine; Citrates; Drug Combinations; Exchange Transfusion, Whole Blood; Humans; Inf | 1987 |
Infant apnea.
Topics: Airway Obstruction; Apnea; Bradycardia; Caffeine; Cardiography, Impedance; Home Nursing; Humans; Inf | 1986 |
Effect of caffeine on pneumogram and apnoea of infancy.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases; | 1986 |
[Peculiarities of drug therapy in childhood].
Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone; | 1986 |
Delay in caffeine elimination in breast-fed infants.
Topics: Apnea; Biological Availability; Bottle Feeding; Breast Feeding; Caffeine; Fatty Acids, Nonesterified | 1987 |
[Effectiveness of low- and high-dose caffeine on idiopathic bradycardia and hypoxemia in premature infants].
Topics: Bradycardia; Caffeine; Citrates; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoxi | 1985 |
Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding.
Topics: Aging; Apnea; Breast Feeding; Caffeine; Cholestasis; Citrates; Drug Combinations; Gestational Age; H | 1985 |
[Apnea periods in the premature infant].
Topics: Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physi | 1974 |
[Treatment of severe generalized scleredema in premature infants].
Topics: Benzoates; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Sclerema Neonatorum; Sodi | 1970 |
Fixed drug combinations and the displacement of bilirubin from albumin.
Topics: Benzoates; Bilirubin; Caffeine; Chromatography, Gel; Diazepam; Drug Synergism; Humans; Infant, Newbo | 1971 |